Key Takeaways:
- Revenue of $77.5 million beat consensus by about $3.3 million
- EPS of $0.04 swung to profit from a $0.03 expected loss
- Cell therapy demand drove the beat across MACI and Epicel
Geri
Vericel swings to profit on $77.5 million Q2 revenue beat
Vericel reported Q2 revenue of $77.5 million, beating consensus by about $3.3 million, and swung to a profit of $0.04 a share.
The Cambridge, Massachusetts-based cell therapy company posted earnings per share of $0.04 for the quarter ended June 30, versus a consensus estimate of a $0.0287 loss. Revenue of $77.46 million topped the $74.14 million analysts expected, a beat of roughly 4.5 percent.
Vericel, which markets MACI for knee cartilage repair, Epicel for severe burns and NexoBrid for burn debridement, reported the results on July 30. The company trades on the Nasdaq under the ticker VCEL.
The beat extends Vericel's run of topping Wall Street estimates as demand for its cell therapy products holds up. The company has built its franchise around MACI, its flagship autologous chondrocyte implant, alongside the burn-care products Epicel and NexoBrid.
The swing to profitability shows the strength of Vericel's cell therapy franchise. Investors will watch the company's earnings call for updated full-year guidance and any signal on MACI procedure growth into the second half of 2026.
This article is for informational purposes only and does not constitute investment advice.
